COST-EFFECTIVENESS OF DOLUTEGRAVIR, A NEW GENERATION INTEGRASE INHIBITOR, IN HIV-1 TREATMENT EXPERIENCED PATIENTS IN FRANCE

被引：0
|
作者：
Despiegel, N. [1 ]
Marcellin, A. G. [2 ]
Aubin, C. [3 ]
Espinas, C. [1 ]
Laurisse, A. [4 ]
Pialoux, G. [5 ]
机构：
[1] Optum, Nanterre, France
[2] Hop La Pitie Salpetriere, AP HP, Paris, France
[3] GlaxoSmithKline, Marly Le Roi, France
[4] ViiV Healthcare France, Marly Le Roi, France
[5] Hop Tenon, AP HP, F-75970 Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2526
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN85
引用
收藏
页码：A678 / A679
页数：3
相关论文
共 50 条
  • [21] Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus
    Castagna, Antonella
    Ferrara, Micol
    Galli, Laura
    Comi, Laura
    Sterrantino, Gaetana
    Cenderello, Giovanni
    Zaccarelli, Mauro
    Foca, Emanuele
    Roncadori, Andrea
    Lazzarin, Adriano
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (01) : 177 - 182
  • [22] Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States
    Butler, Karin
    Anderson, Sarah-Jane
    Hayward, Olivia
    Jacob, Ian
    Punekar, Yogesh Suresh
    Evitt, Lee Alexandra
    Oglesby, Alan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (07): : 891 - 903
  • [23] Cost-effectiveness of Raltegravir in Antiretroviral Treatment-Experienced HIV-1-Infected Patients in Switzerland
    Elbasha, E. E.
    Szucs, T.
    Chaudhary, M. A.
    Kumar, R. N.
    Roediger, A.
    Cook, J. R.
    Opravil, M.
    HIV CLINICAL TRIALS, 2009, 10 (04): : 233 - 253
  • [24] Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients
    Naeger, Lisa K.
    Harrington, Patrick
    Komatsu, Takashi
    Deming, Damon
    ANTIVIRAL THERAPY, 2016, 21 (06) : 481 - 488
  • [25] Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
    Hornberger, J
    Kilby, JM
    Wintfeld, N
    Green, J
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (03) : 240 - 247
  • [26] The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys
    Moss, Lee
    Wagner, David
    Kanaoka, Eri
    Olson, Katie
    Yueh, Yun Lan
    Bowers, Gary D.
    XENOBIOTICA, 2015, 45 (01) : 60 - 70
  • [27] Cost-effectiveness of atazanavir compared to lopinavir in treatment-naive HIV-1 patients in Scotland
    Leen, C.
    Thuresson, P. O.
    Hegg, B.
    Vardeva, K.
    Gosden, T.
    Yogaratnam, J. Z.
    Van Hout, B.
    HIV MEDICINE, 2009, 10 : 41 - 42
  • [28] COST-EFFECTIVENESS ANALYSIS OF COMBINED ANTIRETROVIRAL THERAPIES FOR TREATMENT OF HIV-1 POSITIVE PATIENTS IN BULGARIA
    Djambazov, S.
    Vekov, T.
    VALUE IN HEALTH, 2017, 20 (05) : A77 - A77
  • [29] Dolutegravir for the treatment of adult patients with HIV-1 infection
    Wu, Gary
    Abraham, Teena
    Saad, Nasser
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (05) : 535 - 544
  • [30] Cost-Effectiveness Analysis of Raltegravir in Treatment-Experienced HIV Type 1-Infected Patients in Spain
    Chaudhary, Mohammad A.
    Moreno, Santiago
    Kumar, Ritesh N.
    Nocea, Gonzalo
    Elbasha, Elamin
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (07) : 679 - 689
12345